�Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral pitch systems, proclaimed successful results from the clinical run of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a salutary safety visibility and well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.
The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.
This trial was the low gear to display patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.
ORMD 0801 was good tolerated by all patients and had a proficient safety profile; no good adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically important reductions in glucose as well as C-peptide were observed.
"We are pleased with the results from the Phase 2A trial as they show that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look fore to our next phase of testing and taking the next steps towards making an oral insulin capsule a reality for millions of diabetics about the world."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology initiate in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is quest to revolutionise the treatment of diabetes through its patented flagship product, an orally ingestible insulin space capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit hTTP://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which whitethorn cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, carrying into action or achievements expressed or implied by such fore looking statements, including the risks and uncertainties related to to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional financial support required to conduct its research, exploitation and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause real results, performance or achievements of the company to differ materially from those expressed or implied in such fore looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Oramed Pharmaceuticals
More info
